Amylyx Pharmaceuticals, Inc.AMLXNASDAQ

Revenue (LTM)

-100.0% YoY

Net Income (LTM)

$-145M

+52.0% YoY

Free Cash Flow

$-123M

Revenue CAGR (5Y)

—

Marginsdeclining

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	22	381↑1612.9%	87↓77.1%	0
Gross Profit	0	19	355↑1747.2%	45↓87.3%	-1↓101.2%
Operating Income	-83	-201↓143.5%	39↑119.3%	-315↓911.1%	-153↑51.3%
Net Income	-88	-198↓125.6%	49↑124.8%	-302↓712.4%	-145↑52.0%
EBITDA	-83	-201↓143.1%	40↑119.9%	-291↓829.4%	-144↑50.5%
EPS Diluted	-1.52	-2.98↓96.1%	0.70↑123.5%	-4.43↓732.9%	-1.53↑65.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	50	63↑24.6%	170↑172.2%	77↓54.5%	227↑192.9%
Total Current Assets	105	382↑264.1%	465↑21.6%	189↓59.2%	324↑70.9%
Total Assets	106	391↑270.6%	517↑32.2%	194↓62.6%	333↑71.8%
Total Current Liabilities	17	47↑167.9%	82↑76.0%	28↓65.4%	23↓20.1%
Total Liabilities	257	51↓80.2%	84↑65.2%	29↓65.6%	27↓5.1%
Total Equity	-151	341↑325.3%	433↑27.3%	165↓62.0%	305↑85.3%
Total Debt	0	6	4↓32.5%	2↓53.2%	6↑200.7%
Net Debt	-50	-56↓12.1%	-166↓195.1%	-75↑54.6%	-221↓192.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-75	-180↓140.5%	12↑106.6%	-168↓1506.6%	-123↑26.4%
Capital Expenditure	-0	-3↓615.6%	-1↑50.9%	-0↑87.3%	-0↑12.1%
Free Cash Flow	-75	-182↓142.7%	11↑105.9%	-168↓1671.5%	-123↑26.4%
Stock-Based Comp	3	22↑592.4%	37↑71.1%	33↓11.1%	28↓16.3%
Net Change in Cash	37	13↓65.5%	108↑737.0%	-92↓185.5%	149↑261.6%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance